Back to Search
CAROLYN BRITTEN, MD
Medical Oncology Physician
NPI: 1356375810Individual
Specialties, Licenses & Credentials
Transplant Surgery Physician
Transplant Surgery
Code: 204F00000X
A73704(CA)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A73704(CA)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
34866(SC)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
34866(SC)
Research & Publications (20)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
PMID 17505827·Cancer Chemother Pharmacol·2008
3-trial
Targeting ErbB receptor signaling: a pan-ErbB approach to cancer.
PMID 15486201·Mol Cancer Ther·2004
6-review
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
PMID 10999729·Clin Cancer Res·2000
8-other
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
PMID 10656430·Clin Cancer Res·2000
3-trial
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.
PMID 19259668·Cancer Immunol Immunother·2009
8-other
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
PMID 19299235·Clin Breast Cancer·2009
3-trial
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
PMID 19385713·Clin Pharmacokinet·2009
4-observational
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
PMID 18482274·Liver Int·2009
4-observational
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
PMID 19027958·Mol Immunol·2009
7-preclinical
Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany.
PMID 18982325·Cancer Immunol Immunother·2009
7-preclinical
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
PMID 17721781·Cancer Immunol Immunother·2008
6-review
Toward the harmonization of immune monitoring in clinical trials: quo vadis?
PMID 17721782·Cancer Immunol Immunother·2008
8-other
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.
PMID 17721783·Cancer Immunol Immunother·2008
4-observational
Report on the Fifth Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) April 12-14, 2007 in Würzburg, Germany.
PMID 17922124·Cancer Immunol Immunother·2008
7-preclinical
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
PMID 18043132·Anticancer Drugs·2008
3-trial
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
PMID 17805538·Cancer Chemother Pharmacol·2008
3-trial
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
PMID 18231106·Br J Cancer·2008
6-review
[Concepts for clinical testing of biological agents exemplified for vaccines].
PMID 18487871·Onkologie·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 171 ASHLEY AVE
CHARLESTON, SC 29425 - Phone
- (843) 792-1414
Quick Facts
- NPI
- 1356375810
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 4
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile